以爱尔兰为合作方的多中心随机对照试验中关于国家层面参与情况报告的不足:一项元研究
该元研究纳入239项在爱尔兰招募受试者的多中心随机对照试验,评估国家层面参与情况的报告率。结果显示,报告爱尔兰中心数量的试验占75.3%,报告爱尔兰招募受试者数量的仅占27.2%;在CONSORT指南发表后发表的试验中,仅8.3%报告使用了相关报告指南。作者认为多中心试验的国家层面报告存在不足,建议制定多中心试验扩展版报告指南。
要点
- 239项多中心随机对照试验中,75.3%报告了爱尔兰中心数量,仅27.2%报告了爱尔兰招募受试者数量。
- 在CONSORT发表后发表的试验中,仅8.3%报告使用了相关报告指南。
- 作者认为制定多中心试验扩展版报告指南可能部分解决国家层面报告问题。
核心结论
- 多中心随机对照试验的国家层面报告存在不足,尤其在报告爱尔兰受试者数量和报告使用相关报告指南方面。
- 制定现有报告指南的多中心试验扩展版可能部分解决国家层面报告问题。
研究设计与样本
- 该元研究纳入一项既往研究已识别的在爱尔兰招募受试者的随机对照试验,既往研究检索了六个数据库(从建库至2018年):PubMed、Embase、Scopus、CINAHL、PsychINFO和Cochrane对照试验注册库。
- 本分析聚焦于在医疗环境中开展的人体多中心随机对照试验,且爱尔兰招募受试者比例<80%。
- 共纳入239项随机对照试验,采用描述性统计进行分析。
主要发现
- 最常见的干预类型为药物,占74.9%的随机对照试验;最常见的临床领域为心血管系统,占18.0%。
- 报告爱尔兰中心数量的随机对照试验占75.3%,报告爱尔兰招募受试者数量的占27.2%。
- 在CONSORT报告指南发表后发表的随机对照试验中,8.3%报告使用了相关报告指南。
临床怎么用
- 作者建议制定现有报告指南的多中心试验扩展版,以部分解决国家层面报告问题。
- 作者认为资助、出版、监管研究及雇用研究人员的机构需要确保有足够的规则和激励措施,使试验的所有相关信息得以发表。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Multi-center randomized controlled trials (RCTs) provide vital information about healthcare interventions. Reporting on country-level participation is important for understanding the context of multicenter RCTs. This study aimed to examine multicenter RCT reporting of country-level participation, using Ireland as a case study. STUDY DESIGN AND SETTING: This meta-research study included RCTs identified in a previous study of Irish RCTs. The previous study involved searching six databases (inception-2018) for RCTs with participants recruited in Ireland: PubMed, Embase, Scopus, CINAHL, PsychINFO, and the Cochrane Register of Controlled Trials. This current study focuses on multicenter RCTs conducted on humans in healthcare settings with <80% of participants recruited in Ireland. Outcome variables were trial characteristics and reporting rates for several variables, including the number of Irish centers, number of participants recruited in Ireland, and reporting the use of relevant reporting guidelines. Descriptive statistics were used for analysis. RESULTS: Overall, 239 RCTs were included. The most common intervention was a drug (74.9% of RCTs). The most common clinical domain was the cardiovascular system (18.0%). The number of Irish centers was reported in 75.3% of RCTs and the number of participants recruited in Ireland in 27.2%. Among RCTs that were published after the Consolidated Standards of Reporting in Trials (CONSORT) reporting guideline was published, 8.3% reported using a relevant reporting guideline. CONCLUSION: Our findings show deficits in reporting for multicenter RCTs, particularly in reporting the number of participants in Ireland and reporting the use of relevant reporting guidelines. The development of a multicenter trial extension to existing reporting guidelines may partly address country-level reporting issues. PLAIN LANGUAGE SUMMARY: A randomized controlled trial is a way of assessing the benefits of a medical intervention (like a treatment for a health issue). Randomized trials have at least two different treatment groups. The people taking part are put into one of the groups at random. This process is called "randomization" and is usually done by a computer. These trials are often conducted with people recruited from multiple countries, and Ireland is a country that sometimes plays a role. The key details about trials, such as the number of participants from each country, are often missing from publications related to trials. Information about the number of participants from each country is important, because it shows how applicable the results are to that country or similar countries. We want to find out if trials involving Ireland provide details of how many people from Ireland or how many healthcare centers in Ireland took part in the trial. We did this by looking through the researchers' main publication about the trials and seeing what information they reported. We found 239 trials published between 1968 and 2019, and among those, only 27% detailed the number of participants in Ireland. Three-quarters (75%) of the trials detailed the number of Irish healthcare centers involved. Some researchers are developing a checklist for how to report details of trials conducted across multiple countries; this may help address the shortcomings in the reporting discussed above. In general, those who fund research, publish research, regulate research, and employ researchers need to ensure there are adequate rules and incentives in place so that all relevant information about a trial is published.
引用
- Larkin J, Alanza U, Raj Nagarajan V, et al. Shortcomings in reporting country-level participation in multicenter randomized controlled trials involving Ireland as a collaborating partner: a metaresearch study. J Clin Epidemiol. 2025. PMID: 39988311. doi:10.1016/j.jclinepi.2025.111728
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。